{"disease":{"id":"relapsed-cancer","name":"relapsed cancer"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"olaparib-200-300-mg-bid-daily","indication_name":"Relapsed/refractory metastatic breast cancer (in combination with vorinostat)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib 200-300 mg BID, daily","company_name":"Repare Therapeutics","drug_phase":"discontinued","molecular_target":"PARP1 and PARP2 (poly(ADP-ribose) polymerase enzymes)","drug_class":"PARP inhibitor (DNA damage response inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits PARP enzymes to block DNA single-strand break repair, inducing synthetic lethality in BRCA-mutant and HR-deficient cancers."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT05693831","title":"myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports","phase":"","overall_status":"UNKNOWN","enrollment_count":730,"lead_sponsor_name":"Cellworks Group Inc.","has_results":false},{"nct_id":"NCT05607329","title":"Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Women's Hospital School Of Medicine Zhejiang University","has_results":false},{"nct_id":"NCT01874353","title":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":327,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02983799","title":"Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":272,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02282020","title":"Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":266,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03705156","title":"Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":265,"lead_sponsor_name":"Zai Lab (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT07325136","title":"A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03534453","title":"Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":229,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05060016","title":"A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":222,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT02825420","title":"Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients","phase":"","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"PharmaMar","has_results":true},{"nct_id":"NCT07306559","title":"A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":187,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT06496048","title":"Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Luye Pharma Group Ltd.","has_results":false},{"nct_id":"NCT06681220","title":"Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":166,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT05503888","title":"Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT04718675","title":"A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":135,"lead_sponsor_name":"Kronos Bio","has_results":false},{"nct_id":"NCT03739931","title":"Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT05479487","title":"Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":132,"lead_sponsor_name":"Xiaohua Wu MD","has_results":false},{"nct_id":"NCT04152941","title":"Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients","phase":"","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"ARCAGY/ GINECO GROUP","has_results":false},{"nct_id":"NCT02511795","title":"AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04517357","title":"A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT04998760","title":"A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH )","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":96,"lead_sponsor_name":"Qi Zhou","has_results":false},{"nct_id":"NCT04292119","title":"Lorlatinib Combinations in Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":96,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT05080556","title":"Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT06634589","title":"A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"BeOne Medicines","has_results":false},{"nct_id":"NCT03323398","title":"Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"ModernaTX, Inc.","has_results":true},{"nct_id":"NCT05662397","title":"A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":77,"lead_sponsor_name":"HotSpot Therapeutics, Inc","has_results":false},{"nct_id":"NCT04310345","title":"Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents","phase":"NA","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Vanderbilt-Ingram Cancer Center","has_results":true},{"nct_id":"NCT04420754","title":"Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":70,"lead_sponsor_name":"AffyImmune Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03765099","title":"Animal-Assisted Interactions in Children With Life-Threatening Conditions and Their Parents","phase":"NA","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Vanderbilt-Ingram Cancer Center","has_results":false},{"nct_id":"NCT04797702","title":"Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer.","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":67,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT06644183","title":"Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"Jennifer R. Brown, MD, PhD","has_results":false},{"nct_id":"NCT04887961","title":"Reprab Study: PLD + Trabectedin Rechallenge","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":64,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05274451","title":"A Study to Investigate LYL797 in Adults With Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT03258398","title":"A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"Effector Therapeutics","has_results":false},{"nct_id":"NCT07249879","title":"This Study is an Open-lable, Phase I Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":55,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT06081595","title":"Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":54,"lead_sponsor_name":"Jin Li","has_results":false},{"nct_id":"NCT05922501","title":"Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT07416188","title":"Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT04757779","title":"A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"First People's Hospital of Hangzhou","has_results":false},{"nct_id":"NCT04510636","title":"Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT04421560","title":"Pembrolizumab, Ibrutinib and Rituximab in PCNSL","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT05852717","title":"Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Dipenkumar Modi","has_results":false},{"nct_id":"NCT04275102","title":"Three Times Weekly Symptom Screening for Children With Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"The Hospital for Sick Children","has_results":false},{"nct_id":"NCT04092179","title":"Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT06750952","title":"Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03445858","title":"Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Children's Hospital Medical Center, Cincinnati","has_results":false},{"nct_id":"NCT02258607","title":"Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":21,"lead_sponsor_name":"Sierra Oncology LLC - a GSK company","has_results":false},{"nct_id":"NCT05053295","title":"Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Gangnam Severance Hospital","has_results":false},{"nct_id":"NCT03406715","title":"Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT03187288","title":"Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"University Health Network, Toronto","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}